Literature DB >> 23103127

Indoleamine 2,3 dioxygenase and metabolic control of immune responses.

David H Munn1, Andrew L Mellor.   

Abstract

Sustained access to nutrients is a fundamental biological need, especially for proliferating cells, and controlling nutrient supply is an ancient strategy to regulate cellular responses to stimuli. By catabolizing the essential amino acid TRP, cells expressing the enzyme indoleamine 2,3 dioxygenase (IDO) can mediate potent local effects on innate and adaptive immune responses to inflammatory insults. Here, we discuss recent progress in elucidating how IDO activity promotes local metabolic changes that impact cellular and systemic responses to inflammatory and immunological signals. These recent developments identify potential new targets for therapy in a range of clinical settings, including cancer, chronic infections, autoimmune and allergic syndromes, and transplantation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103127      PMCID: PMC3594632          DOI: 10.1016/j.it.2012.10.001

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  82 in total

1.  HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism.

Authors:  Olivier Manches; David Munn; Anahita Fallahi; Jeffrey Lifson; Laurence Chaperot; Joel Plumas; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

2.  Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells.

Authors:  Maria T Pallotta; Ciriana Orabona; Claudia Volpi; Carmine Vacca; Maria L Belladonna; Roberta Bianchi; Giuseppe Servillo; Cinzia Brunacci; Mario Calvitti; Silvio Bicciato; Emilia M C Mazza; Louis Boon; Fabio Grassi; Maria C Fioretti; Francesca Fallarino; Paolo Puccetti; Ursula Grohmann
Journal:  Nat Immunol       Date:  2011-07-31       Impact factor: 25.606

3.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

Review 4.  Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism.

Authors:  M W Taylor; G S Feng
Journal:  FASEB J       Date:  1991-08       Impact factor: 5.191

5.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

6.  Modulation of tryptophan catabolism by regulatory T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Kwang Woo Hwang; Ciriana Orabona; Carmine Vacca; Roberta Bianchi; Maria Laura Belladonna; Maria Cristina Fioretti; Maria-Luisa Alegre; Paolo Puccetti
Journal:  Nat Immunol       Date:  2003-10-26       Impact factor: 25.606

7.  Severe tryptophan starvation blocks onset of conventional persistence and reduces reactivation of Chlamydia trachomatis.

Authors:  Ralf M Leonhardt; Seung-Joon Lee; Paula B Kavathas; Peter Cresswell
Journal:  Infect Immun       Date:  2007-08-27       Impact factor: 3.441

8.  Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption.

Authors:  Lee Jia; Karen Schweikart; Joseph Tomaszewski; John G Page; Patricia E Noker; Sarah A Buhrow; Joel M Reid; Matthew M Ames; David H Munn
Journal:  Food Chem Toxicol       Date:  2007-08-10       Impact factor: 6.023

9.  Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease.

Authors:  Luigina Romani; Francesca Fallarino; Antonella De Luca; Claudia Montagnoli; Carmen D'Angelo; Teresa Zelante; Carmine Vacca; Francesco Bistoni; Maria C Fioretti; Ursula Grohmann; Brahm H Segal; Paolo Puccetti
Journal:  Nature       Date:  2008-01-10       Impact factor: 49.962

10.  IDO and regulatory T cell support are critical for cytotoxic T lymphocyte-associated Ag-4 Ig-mediated long-term solid organ allograft survival.

Authors:  Robert Sucher; Klaus Fischler; Rupert Oberhuber; Irmgard Kronberger; Christian Margreiter; Robert Ollinger; Stefan Schneeberger; Dietmar Fuchs; Ernst R Werner; Katrin Watschinger; Bettina Zelger; George Tellides; Nina Pilat; Johann Pratschke; Raimund Margreiter; Thomas Wekerle; Gerald Brandacher
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

View more
  393 in total

1.  Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients.

Authors:  Kerry-Ann McDonald; Tsutomu Kawaguchi; Qianya Qi; Xuan Peng; Mariko Asaoka; Jessica Young; Mateusz Opyrchal; Li Yan; Santosh Patnaik; Eigo Otsuji; Kazuaki Takabe
Journal:  Ann Surg Oncol       Date:  2019-04-08       Impact factor: 5.344

2.  IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis.

Authors:  M T Isla Larrain; M E Rabassa; E Lacunza; A Barbera; A Cretón; A Segal-Eiras; M V Croce
Journal:  Tumour Biol       Date:  2014-04-01

Review 3.  Evolution to a chronic disease niche correlates with increased sensitivity to tryptophan availability for the obligate intracellular bacterium Chlamydia pneumoniae.

Authors:  Wilhelmina M Huston; Christopher J Barker; Anu Chacko; Peter Timms
Journal:  J Bacteriol       Date:  2014-03-28       Impact factor: 3.490

4.  Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells.

Authors:  Min-Hee Oh; Im-Hong Sun; Liang Zhao; Robert D Leone; Im-Meng Sun; Wei Xu; Samuel L Collins; Ada J Tam; Richard L Blosser; Chirag H Patel; Judson M Englert; Matthew L Arwood; Jiayu Wen; Yee Chan-Li; Lukáš Tenora; Pavel Majer; Rana Rais; Barbara S Slusher; Maureen R Horton; Jonathan D Powell
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

Review 5.  Metabolic Barriers to T Cell Function in Tumors.

Authors:  Ayaka Sugiura; Jeffrey C Rathmell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

6.  Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1).

Authors:  Catherine White; Meredeth A McGowan; Hua Zhou; Nunzio Sciammetta; Xavier Fradera; Jongwon Lim; Elizabeth M Joshi; Christine Andrews; Elliott B Nickbarg; Phillip Cowley; Sarah Trewick; Martin Augustin; Konstanze von Köenig; Charles A Lesburg; Karin Otte; Ian Knemeyer; Hyun Woo; Wensheng Yu; Mangeng Cheng; Peter Spacciapoli; Prasanthi Geda; Xuelei Song; Nadya Smotrov; Patrick Curran; Mee Ra Heo; Pravien Abeywickrema; J Richard Miller; David Jonathan Bennett; Yongxin Han
Journal:  ACS Med Chem Lett       Date:  2020-03-10       Impact factor: 4.345

7.  Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors.

Authors:  Brendan T Parr; Richard Pastor; Benjamin D Sellers; Zhonghua Pei; Firoz A Jaipuri; Georgette M Castanedo; Lewis Gazzard; Sanjeev Kumar; Xiaokai Li; Wen Liu; Rohan Mendonca; Roheeth K Pavana; Hima Potturi; Cheng Shao; Venkata Velvadapu; Jesse P Waldo; Guosheng Wu; Po-Wai Yuen; Zuhui Zhang; Yamin Zhang; Seth F Harris; Angela J Oh; Antonio DiPasquale; Kevin Dement; Hank La; Leanne Goon; Amy Gustafson; Erica C VanderPorten; Mario R Mautino; Yichin Liu
Journal:  ACS Med Chem Lett       Date:  2020-03-04       Impact factor: 4.345

Review 8.  Learning from other diseases: protection and pathology in chronic fungal infections.

Authors:  Teresa Zelante; Giuseppe Pieraccini; Lucia Scaringi; Franco Aversa; Luigina Romani
Journal:  Semin Immunopathol       Date:  2015-09-17       Impact factor: 9.623

Review 9.  Targeting Type 1 Diabetes: Selective Approaches for New Therapies.

Authors:  Daniel F Sheehy; Sean P Quinnell; Arturo J Vegas
Journal:  Biochemistry       Date:  2019-01-17       Impact factor: 3.162

10.  Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.

Authors:  Etsuko Miyagi; Yasuyo Maruyama; Tae Mogami; Reiko Numazaki; Atsuko Ikeda; Hiroshi Yamamoto; Fumiki Hirahara
Journal:  Int J Clin Oncol       Date:  2016-09-13       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.